Title: Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
Authors: DEKEMPENEER YANACAVELIERS VICKYD'HUYVETTER MATTHIASMAERTENS DOMINICGYSEMANS M.OOMS MAARTENLAHOUTTE TONYXAVIER CATHARINABRUCHERTSEIFER FRANKMORGENSTERN ALFREDCARDINAELS THOMAS
Citation: JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES vol. 50 no. 1 p. S7-S8
Publisher: ELSEVIER BV
Publication Year: 2019
JRC N°: JRC116460
ISSN: 1939-8654 (online)
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC116460
DOI: 10.1016/j.jmir.2019.03.024
Type: Articles in periodicals and books
Abstract: This study investigates a novel targeted therapy which combines the α-emitter Bismuth-213 (213Bi) and HER2-targeting nanobodies (Nbs) to selectively kill HER2+ metastases in breast- and ovarian cancer. The use of nanobodies as vehicles in TAT is promising due to their excellent in vivo properties, high affinity and specificity, fast diffusion and clearance kinetics. Moreover, Nbs show good tumor penetration due to their small size. The aim of this study is to develop and evaluate the in vitro binding characteristics on HER+ SKOV-3 cells, the in vitro stability using radio-ITLC and HPLC and the in vivo biodistribution of 213Bi-DTPA HER2 targeting Nb.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.